Paraproteinaemia in Primary Cutaneous Marginal Zone Lymphoma.

Primary cutaneous marginal zone lymphomas (PCMZL) frequently exhibit lymphoplasmacytoid/plasmacytic differentiation, implying the capacity to produce monoclonal immunoglobulins. As these paraproteins are secreted, and thus are measurable in blood and urine, they may correlate with disease burden and serve as tumour markers reflecting therapeutic response. This study retrospectively analysed the records of 23 patients with PCMZL. During treatment and follow-up, laboratory tests, including full blood count, lactate dehydrogenase, serum protein electrophoresis and turbidimetric analyses, were conducted. Thirty-nine percent of cases showed a suspicious serum protein electrophoresis in terms of paraproteinaemia. In 44% of cases the heavy and light chain restriction in tissue samples correlated with serological findings. Altogether, 89% of the PCMZL patients with paraproteinaemia eventually experienced a relapse, in contrast to 62% of the group without paraproteinaemia. This study analysed the incidence and clinical implications of paraproteinaemia in patients with PCMZL. A clear correlation was found between paraproteinaemia, tumour relapse and therapeutic intervention.

[1]  A. Rosenwald,et al.  Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal‐zone lymphoma with a nonclass‐switched immunoglobulin M immunophenotype , 2017, The British journal of dermatology.

[2]  M. Wobser,et al.  Cutaneous B‐cell lymphomas – pathogenesis, diagnostic workup, and therapy , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  A. Rosenwald,et al.  Lack of myeloid differentiation primary response protein MyD88 L265P mutation in primary cutaneous marginal zone lymphoma , 2015, The British journal of dermatology.

[4]  A. Kerstan,et al.  Primary cutaneous marginal zone lymphoma with sequential development of nodal marginal zone lymphoma in a patient with selective immunoglobulin A deficiency , 2013, Journal of cutaneous pathology.

[5]  C. Muniesa,et al.  Is bone marrow biopsy always indicated in patients with primary cutaneous marginal zone B-cell lymphoma? , 2013, Actas dermo-sifiliograficas.

[6]  A. Rosenwald,et al.  Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression , 2013, Modern Pathology.

[7]  C. Sander,et al.  Primary cutaneous B‐cell lymphomas , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  T. Molina,et al.  Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. , 2011, American journal of clinical pathology.

[9]  S. Pasricha,et al.  Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemia , 2011, Journal of Clinical Pathology.

[10]  S. Swerdlow,et al.  Cutaneous Marginal Zone Lymphomas Have Distinctive Features and Include 2 Subsets , 2010, The American journal of surgical pathology.

[11]  B. Dréno,et al.  Routine bone marrow biopsy in the initial evaluation of primary cutaneous B-cell lymphoma does not appear justified. , 2009, European journal of dermatology : EJD.

[12]  塩沢 英輔,et al.  Lymphoplasmacytic lymphoma / Waldenström macroglobulinemia (LPL / WM) , 2009 .

[13]  R. Bende,et al.  The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. , 2008, Blood.

[14]  Angelica Selim,et al.  TNM Classification System for Primary Cutaneous Lymphomas , 2008 .

[15]  R. Dummer,et al.  European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. , 2008, Blood.

[16]  C. Meijer,et al.  Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Medeiros,et al.  Primary cutaneous marginal zone B-cell lymphoma. , 2006, American journal of clinical pathology.

[18]  Stefan Wohrer,et al.  Monoclonal gammmopathy (MG) in extranodal marginal zone lymphoma (ENMZL) , 2005, American journal of hematology.

[19]  D. Slater,et al.  The new World Health Organization–European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants , 2005, The British journal of dermatology.

[20]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[21]  B. Kasravi,et al.  Understanding and interpreting serum protein electrophoresis. , 2005, American family physician.

[22]  T. Economopoulos,et al.  Monoclonal gammopathies in B-cell non-Hodgkin's lymphomas. , 2003, Leukemia research.

[23]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[24]  F. Alt,et al.  Mechanism and control of class-switch recombination. , 2002, Trends in immunology.

[25]  J. Olsen,et al.  Cancer risk in patients with monoclonal gammopathy of undetermined significance , 2000, American journal of hematology.

[26]  R. Kyle,et al.  The spectrum of IgM monoclonal gammopathy in 430 cases. , 1987, Mayo Clinic proceedings.

[27]  E. Pascali,et al.  Serum and urine monoclonal immunoglobulins in malignant non-Hodgkin's lymphoma. , 1986, Acta haematologica.

[28]  R. Alexanian Monoclonal gammopathy in lymphoma. , 1975, Archives of internal medicine.